Gene therapy for Duchenne is centered on the goal of successfully introducing a smaller, but efficient version of dystrophin into the muscle cell. RGX-202 is an investigational gene therapy product, utilizing a novel adeno-associated virus (AAV8) to transport a shortened version of the dystrophin gene (micro-dystrophin) that may provide benefit in place of the missing full-length dystrophin protein.

Status

AFFINITY DUCHENNE a Phase 1/2 study is not yet recruiting. The FDA approved the IND for RGX-202 and it is anticipated to begin enrollment in the first half of 2022.

Sponsor

This program is sponsored by REGENXBIO.

Media